No Data
No Data
OS Therapies Announces Development of Two Novel Tunable Antibody Drug Conjugate (TADC)-Based Therapeutic Candidates
Express News | Os Therapies Announces Development of Two Novel Tunable Antibody Drug Conjugate (Tadc)-Based Therapeutic Candidates
OS Therapies Reports Positive Preclinical Data for Ovarian Cancer Treatment | NYSE-A:OSTX
Express News | Os Therapies Inc: Strong Safety Profile for Fra-H With No Loss of Bodyweight as Compared With Control in Animal Models
Express News | Os Therapies Inc: Strong Efficacy for Fra-H in KB and Igrov-1 Mouse Models of Ovarian Cancer
OS Therapies Announces Positive Efficacy and Safety Data for Ovarian Cancer Therapeutic Candidate Developed Based on Tunable Antibody Drug Conjugate (TADC) Platform Using Proprietary Silicone Linker Platform in Preclinical Models
No Data
No Data